Are SPACs Better Than Traditional IPOs?
Published: Mar 10, 2021 By Kate Goodwin
Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
News
Outcome Capital Launches Pharmacy and Related Services Advisory Board to Advance Innovation Across the Healthcare Sector
Thom Stambaugh, recognized leader in pharmacy innovation and care delivery transformation, will serve as inaugural member Boston, MA – November 12, 2025 — Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced the formation of its Pharmacy and Related Services Advisory Board, a new initiative within the […]
Read MoreResources
Outcome Capital Life Science Market Pulse, October 2025
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
